StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$17.73+1.03 (+6.17%)

Close on Nov 18, 2026Market cap $1.75BP/E –Yield –

Ultragenyx Pharmaceutical price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Ultragenyx Pharmaceutical's price to sales ratio was 2.3× on Nov 11, 2026, against 5.3× a year earlier. Over the last 5 years it ranged from 2.1× to 15.9×, with a median of 7.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.3×−1.2
2025Dec 31, 20253.5×−3.9
2024Dec 31, 20247.4×−1.0
2023Dec 29, 20238.4×−1.0
2022Dec 30, 20229.5×−6.4
2021Dec 31, 202115.9×−23.2
2020Dec 31, 202039.1×+9.9
2019Dec 31, 201929.2×−29.1
2018Dec 31, 201858.4×–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?